ATE528016T1 - Virusähnliche partikel als paramyxovirus- impfstoffe - Google Patents

Virusähnliche partikel als paramyxovirus- impfstoffe

Info

Publication number
ATE528016T1
ATE528016T1 AT06800719T AT06800719T ATE528016T1 AT E528016 T1 ATE528016 T1 AT E528016T1 AT 06800719 T AT06800719 T AT 06800719T AT 06800719 T AT06800719 T AT 06800719T AT E528016 T1 ATE528016 T1 AT E528016T1
Authority
AT
Austria
Prior art keywords
virus
particles
vlps
vaccines
interest
Prior art date
Application number
AT06800719T
Other languages
English (en)
Inventor
Trudy Morrison
Homer Pantua
Original Assignee
Univ Massachusetts Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts Medical filed Critical Univ Massachusetts Medical
Application granted granted Critical
Publication of ATE528016T1 publication Critical patent/ATE528016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18423—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18623—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06800719T 2005-08-05 2006-08-03 Virusähnliche partikel als paramyxovirus- impfstoffe ATE528016T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70612605P 2005-08-05 2005-08-05
US11/497,888 US7951384B2 (en) 2005-08-05 2006-08-02 Virus-like particles as vaccines for paramyxovirus
PCT/US2006/030319 WO2007019247A2 (en) 2005-08-05 2006-08-03 Virus-like particles as vaccines for paramyxovirus

Publications (1)

Publication Number Publication Date
ATE528016T1 true ATE528016T1 (de) 2011-10-15

Family

ID=37727898

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06800719T ATE528016T1 (de) 2005-08-05 2006-08-03 Virusähnliche partikel als paramyxovirus- impfstoffe

Country Status (13)

Country Link
US (2) US7951384B2 (de)
EP (1) EP1917033B1 (de)
JP (2) JP5342234B2 (de)
KR (1) KR101120784B1 (de)
CN (1) CN101282744B (de)
AT (1) ATE528016T1 (de)
AU (1) AU2006278588A1 (de)
BR (1) BRPI0614702A2 (de)
CA (1) CA2617508C (de)
IL (1) IL189313A (de)
NZ (1) NZ565961A (de)
RU (1) RU2008106445A (de)
WO (1) WO2007019247A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH668505A5 (de) 1985-03-20 1988-12-30 Bbc Brown Boveri & Cie Halbleiterbauelement.
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2008061243A2 (en) * 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
CA2678966A1 (en) * 2007-02-21 2008-08-28 Novavax, Inc. Chimeric newcastle disease virus vlps
US20110008838A1 (en) * 2007-07-19 2011-01-13 Gale Smith Chimeric varicella zoster virus virus-like particles
EP2217699A4 (de) * 2007-10-22 2012-11-28 Univ Rochester Respiratorisches-syncytial-virus-impfstoff auf der grundlage chimärer papillomavirus-ähnlicher partikel oder capsomeren
US20110014231A1 (en) * 2007-11-05 2011-01-20 Mor Research Applications Ltd Anti-measles cancer immunotherapy
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2009132195A1 (en) * 2008-04-23 2009-10-29 Michigan State University Immortal avian cell line and methods of use
JP2010122205A (ja) * 2008-08-29 2010-06-03 Sysmex Corp 麻疹ウイルス検出方法、メンブレンアッセイ用試験具およびメンブレンアッセイ用試験キット
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
PL2370099T3 (pl) * 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
EP2414386B1 (de) * 2009-04-03 2016-01-27 Merial Limited Vogelimpfstoffe mit newcastle-krankheit-vektor
CA2768186A1 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
CN103977394B (zh) * 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10633667B2 (en) * 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
EP2591114B1 (de) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisierung grosser säugetiere durch niedrige dosen von rna
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EP2729165B1 (de) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
EP4241785B1 (de) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenzavirus-impfstoffe und verwendungen davon
KR101374192B1 (ko) * 2011-12-21 2014-03-14 대한민국 제4형 조류파라믹소바이러스 ｈｎ 단백질 및 이를 포함하는 ｈｉ법 검사용 항원진단액
CN104220091A (zh) * 2012-02-14 2014-12-17 科学与工业研究会 能结合流感血细胞凝集素蛋白的合成肽
CN102618668B (zh) * 2012-03-27 2013-08-28 广西壮族自治区兽医研究所 鸭新城疫病毒和鸭圆环病毒二重pcr检测试剂盒
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
EP3798310A1 (de) 2013-03-14 2021-03-31 Emory University Rekombinante rsv mit stillen mutationen, impfstoffe und zugehörige verfahren
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR101546064B1 (ko) 2013-07-29 2015-08-20 건국대학교 산학협력단 인플루엔자 바이러스 매트릭스 1 단백질과 뉴캣슬 병 바이러스 융합 단백질을 발현하는 뉴캣슬 병 바이러스 바이러스 유사입자
CN104721817B (zh) * 2013-12-19 2018-04-17 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN103805600A (zh) * 2014-03-06 2014-05-21 福州大学 一种dna分子克隆方法
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US10314906B2 (en) 2015-03-18 2019-06-11 University Of Massachusetts Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease
CA2996007A1 (en) 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
WO2017087550A1 (en) * 2015-11-16 2017-05-26 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
US10316295B2 (en) * 2015-12-17 2019-06-11 The Penn State Research Foundation Paramyxovirus virus-like particles as protein delivery vehicles
US12600956B2 (en) 2015-12-17 2026-04-14 The Penn State Research Foundation Paramyxovirus virus-like particles as protein delivery vehicles
EP3246410A1 (de) * 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv-hybridviren zur onkolytischen therapie von krebs
EP3255056A1 (de) * 2016-06-06 2017-12-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Verfahren zur herstellung von selbstorganisierenden paramyxoviralnukleocapsidähnlichen partikeln und verwendungen davon
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EP3518967A4 (de) 2016-10-03 2020-04-29 University of Massachusetts Verfahren zur immunisierung von präimmunen personen gegen das respiratorische synzytialvirus (rsv)
CN106636015B (zh) * 2016-12-20 2019-12-10 吉林大学 一种嵌合型新城疫病毒样颗粒的制备方法
EP3595676A4 (de) * 2017-03-17 2021-05-05 Modernatx, Inc. Rna-impfstoffe gegen zoonosen
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN112638411B (zh) * 2018-05-04 2025-03-04 斯拜生物技术有限公司 疫苗组合物
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN113382748A (zh) 2018-09-24 2021-09-10 马萨诸塞大学 用于制备和使用病毒样颗粒(vlp)的组合物和方法
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
CN110628724B (zh) * 2019-09-25 2023-04-14 兰州生物制品研究所有限责任公司 一种三型副流感病毒野毒株及其应用
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
CN112500494B (zh) * 2020-11-09 2023-01-24 昆明市妇幼保健院 用于新型冠状病毒检测的抗原及其制备方法
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN113214366B (zh) * 2021-05-25 2023-03-03 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种重组新城疫病毒基质蛋白及其应用
CN114574452B (zh) * 2021-12-29 2023-07-21 扬州大学 Hn基因易位构建重组新城疫疫苗候选株vii-hnf的方法及用途
CN116479175B (zh) * 2023-03-13 2024-10-18 广州国家实验室 用于检测人副流感病毒核酸的检测系统、试剂盒及方法
CN119431521B (zh) * 2024-10-16 2025-12-16 郑州伊美诺生物技术有限公司 人ⅰ型副流感病毒hn重组抗原及其应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2518755B1 (fr) * 1981-12-23 1986-04-11 Pasteur Institut Sonde contenant un acide nucleique modifie et reconnaissable par des anticorps specifiques et utilisation de cette sonde pour detecter et caracteriser une sequence d'adn homologue
US6022958A (en) * 1986-08-13 2000-02-08 Bayer Corporation cDNAs coding for members of the carcinoembryonic antigen family
US4774339A (en) * 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5250431A (en) 1988-06-13 1993-10-05 Dana-Farber Cancer Institute, Inc. Alteration of the interaction of a T-cell receptor with a proteintyrosine kinase
US5486599A (en) 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5690938A (en) * 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5274113A (en) * 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) * 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5589372A (en) 1990-09-26 1996-12-31 E. R. Squibb & Sons, Inc. Squalene synthetase
US5248782A (en) * 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) * 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US5847096A (en) 1991-08-30 1998-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA constructs encoding CD4 fusion proteins
WO1993009141A1 (en) 1991-11-01 1993-05-13 Joslin Diabetes Center Antigen associated with type i diabetes mellitus
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US5939283A (en) 1992-12-31 1999-08-17 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
DK0678034T3 (da) * 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
WO1994016081A1 (de) 1993-01-16 1994-07-21 Manfred Schawaller Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
AUPM368994A0 (en) 1994-02-04 1994-02-24 Saramane Pty Ltd Malaria merozoite antigen subunit vaccine
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
FR2717498B1 (fr) 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
US5851993A (en) 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
US5583816A (en) 1994-06-29 1996-12-10 Sgs-Thomson Microelectronics, Inc. Long write test
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6913881B1 (en) * 1996-01-24 2005-07-05 Third Wave Technologies, Inc. Methods and compositions for detecting target sequences
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
US6423316B1 (en) 1997-03-26 2002-07-23 Imperial College Innovative Limited Anticoagulant fusion protein anchored to cell membrane
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
NZ538399A (en) 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US7105488B1 (en) 1998-02-27 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services G protein-coupled receptor antagonists
EP0974660A1 (de) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle-Krankheitsvirus Infektiöser Klone, Impfstoffe und Diagnosetest
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6355786B1 (en) 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
WO2000055181A1 (en) 1999-03-15 2000-09-21 The General Hospital Corporation Methods of modulating cell attachment and migration
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6306628B1 (en) * 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
EP1156111A1 (de) 2000-05-19 2001-11-21 Stichting Dienst Landbouwkundig Onderzoek Chimäre Arterivirus-ähnliche Partikel
DK1294771T3 (da) 2000-06-12 2008-12-15 Univ Saskatchewan Kimært GapC-protein fra Streptococcus og anvendelse deraf til vaccinering og diagnosticering
AUPQ841800A0 (en) 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
WO2002012454A1 (en) * 2000-08-08 2002-02-14 The Kitasato Institute Virus-like micrograins and process for producing the same
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
JP2002079971A (ja) * 2000-09-06 2002-03-19 Honda Motor Co Ltd 車両用ウインドシールド
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
WO2002077195A2 (en) 2001-03-26 2002-10-03 Walter Reed Army Institute Of Research Plasmodium falciparum ama-1 protein and uses thereof
AU2002258621A1 (en) 2001-03-28 2002-10-21 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
CN1636050A (zh) 2001-04-24 2005-07-06 基因创新有限公司 核心糖基化hcv包膜蛋白
US7005254B2 (en) 2001-06-07 2006-02-28 Rigel Pharmaceuticals, Incorporated LETM1: modulators of cellular proliferation
US6695545B2 (en) 2001-10-11 2004-02-24 Gregory M. Boston Soil stabilization composition
US7101566B2 (en) 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
WO2004067032A2 (en) 2003-01-24 2004-08-12 University Of Massachusetts Medical Center Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
CN1820020B (zh) * 2003-05-06 2010-04-28 技术持有有限公司 Sars-冠状病毒病毒样颗粒以及应用方法
WO2004101598A2 (en) 2003-05-09 2004-11-25 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
EP1651671A2 (de) 2003-07-30 2006-05-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Agonisten des epha2-t-zellen-epitops und deren verwendung
CA2536735C (en) 2003-09-05 2013-01-22 Genencor International, Inc. Methods for determining cd8+ t-cell epitopes
CA2678966A1 (en) * 2007-02-21 2008-08-28 Novavax, Inc. Chimeric newcastle disease virus vlps

Also Published As

Publication number Publication date
EP1917033A2 (de) 2008-05-07
US20070178120A1 (en) 2007-08-02
HK1125051A1 (en) 2009-07-31
BRPI0614702A2 (pt) 2011-04-12
CA2617508C (en) 2013-12-31
NZ565961A (en) 2011-11-25
JP2013176375A (ja) 2013-09-09
CA2617508A1 (en) 2007-02-15
AU2006278588A1 (en) 2007-02-15
KR101120784B1 (ko) 2012-04-20
JP2009502204A (ja) 2009-01-29
EP1917033B1 (de) 2011-10-12
WO2007019247A2 (en) 2007-02-15
KR20080072627A (ko) 2008-08-06
IL189313A (en) 2015-10-29
IL189313A0 (en) 2008-06-05
US9399059B2 (en) 2016-07-26
RU2008106445A (ru) 2009-09-10
CN101282744A (zh) 2008-10-08
EP1917033A4 (de) 2009-09-02
US7951384B2 (en) 2011-05-31
WO2007019247A3 (en) 2008-01-17
JP5342234B2 (ja) 2013-11-13
CN101282744B (zh) 2012-01-04
US20090068221A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
ATE528016T1 (de) Virusähnliche partikel als paramyxovirus- impfstoffe
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
NZ595736A (en) Chimeric viruses presenting non-native surface proteins and uses thereof
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
ATE426412T1 (de) Adjuvante influenza-vakzine
EP2525816A4 (de) Gerichtete präsentation eines heterologen antigens auf calicivirusähnlichen partikeln
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
DK1881845T3 (da) Nipah-virusvacciner
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
EA201100674A1 (ru) Вакцина против вируса африканской чумы лошадей
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
ATE450545T1 (de) Impfstoff mit lawsonia intracellularis- untereinheit
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
DK1664097T3 (da) Piroplasmidvaccine
ATE450546T1 (de) Impfstoffe mit ornithobakterium rhinotracheale- untereinheit
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
TH98990A (th) ไคเมอริกไวรัสซึ่งแสดงโปรตีนพื้นผิวแบบไม่ใช่โปรตีนธรรมชาติและการใช้ไคเมอริกไวรัสเหล่านี้

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties